Psoriasis: A Complete Guide to Understanding and Managing Psoriasis

Psoriasis is a chronic, immune-mediated skin disease in which an overactive IL-23 and IL-17 immune response shortens the skin cell cycle from about 28 days to 3 or 4 days, producing raised, scaly plaques in roughly 2 to 3 percent of people worldwide. Its rarest and most severe form, erythrodermic psoriasis, means psoriasis with redness and scaling covering more than 90 percent of the body surface, according to a 2023 review by Potestio and colleagues, and it needs urgent medical care.

If you or someone you know has psoriasis, you have probably heard it described as “just a skin condition.” But if you live with it, you know it is far more than that. Those thick, silvery-white patches that crack, bleed, and itch are the visible part of a disease that often affects joints, cardiovascular health, and emotional well-being.

The encouraging news is that psoriasis treatment has advanced dramatically in the past two decades. We now have therapies that can clear the skin almost entirely for many patients. Dermatologists match those therapies to the type and severity of psoriasis, from plaque psoriasis (psoriasis vulgaris) on the elbows to erythrodermic psoriasis across the whole body, and integrative strategies can support overall health alongside conventional care. The psoriasis condition overview on Regenerated.com gives a shorter summary of the same disease.

What Is Psoriasis?

Psoriasis is a chronic autoimmune disease in which the immune system sends faulty signals that speed up the growth cycle of skin cells. Normally, new skin cells form deep in the skin and slowly rise to the surface over about a month, then quietly shed. In psoriasis, this process is compressed to just three or four days. The result is a pileup of cells on the skin surface that forms the characteristic raised, red (or dark) patches covered with silvery scales.^[1]

Unlike eczema, which is driven primarily by the Th2 arm of the immune system, psoriasis involves the Th17 and Th1 pathways. Key inflammatory molecules include tumor necrosis factor alpha (TNF-alpha), interleukin-17 (IL-17), and interleukin-23 (IL-23). Understanding these pathways has been the basis for a revolution in treatment.^[2]

Psoriasis is not contagious. You cannot get it from touching someone who has it. And while it can start at any age, it most commonly appears for the first time between the ages of 15 and 35, with a second peak around ages 50 to 60.^[3]

Clinicians often call psoriasis a chronic inflammatory or immune-mediated disease rather than only a skin disease, because the same inflammation reaches the joints, blood vessels, and metabolism. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, describes psoriasis as a long-lasting disease with periods of flares and calmer stretches.

Types of Psoriasis

Psoriasis takes several forms, and it is possible to have more than one type at the same time or to transition from one type to another.

Plaque Psoriasis

By far the most common type, accounting for about 80-90% of cases. It presents as well-defined, raised patches (plaques) of red or darkened skin topped with silvery-white scales. Common locations include the elbows, knees, lower back, and scalp. Plaques can range from small spots to areas covering large portions of the body.^[1]

Guttate Psoriasis

Characterized by small, drop-shaped spots, guttate psoriasis often appears suddenly, typically in children or young adults. It is frequently triggered by a streptococcal throat infection. In many cases it resolves on its own within weeks to months, though some people go on to develop chronic plaque psoriasis.^[4]

Inverse Psoriasis

This type shows up in skin folds: the armpits, groin, under the breasts, and between the buttocks. Instead of thick scales, inverse psoriasis produces smooth, shiny, red patches that can be confused with fungal infections. Friction and sweating make this type particularly uncomfortable.

Pustular Psoriasis

Marked by white, pus-filled bumps (pustules) surrounded by red skin. The pus is not infected; it consists of white blood cells. Pustular psoriasis can be localized (often on the palms and soles) or generalized across the body, which is a medical emergency requiring immediate care.^[5]

The generalized form, generalized pustular psoriasis (GPP, once called von Zumbusch psoriasis), now has a targeted treatment. Spesolimab, an antibody that blocks the interleukin-36 receptor, reduced pustules within a week in the Effisayil 1 trial reported by Bachelez and colleagues in the New England Journal of Medicine (2021), and the FDA approved it for GPP flares in 2022.^[38] The pustular psoriasis guide covers the palmoplantar and generalized forms in more depth.

Erythrodermic Psoriasis

The rarest and most severe form, erythrodermic psoriasis causes widespread redness and shedding of skin over large areas of the body. It can disrupt the body’s ability to regulate temperature and fluid balance and requires urgent medical attention. It can be triggered by severe sunburn, abrupt withdrawal of systemic steroids, or poorly controlled psoriasis.^[5]

Erythrodermic psoriasis means psoriasis that covers more than 90 percent of the body surface with redness and scaling, the definition used in a 2023 review by Potestio and colleagues; an earlier review by Singh and colleagues (2016) used a threshold of at least 75 percent.^[34][35] The section on erythrodermic psoriasis below explains the warning signs, causes, and treatment.

Nail Psoriasis

Up to 50% of people with plaque psoriasis and about 80% of those with psoriatic arthritis develop nail changes. These can include pitting (tiny dents), discoloration (yellow-brown spots called “oil drops”), thickening, crumbling, and separation of the nail from the nail bed (onycholysis).^[6] The nail psoriasis article walks through treatment options for fingernails and toenails.

Scalp Psoriasis

Scalp involvement is extremely common and can range from mild flaking that resembles dandruff to thick, crusted plaques covering the entire scalp. It can extend beyond the hairline onto the forehead, behind the ears, and down to the nape of the neck.

Psoriasis Terms and What They Mean

Each psoriasis term describes a specific pattern. The table below matches each name to its defining feature, which is how dermatology exams and patient quizzes usually test them.

What Does Erythrodermic Psoriasis Mean?

Erythrodermic psoriasis means psoriasis that has spread to cover nearly the entire body with redness, scaling, and shedding skin. Potestio and colleagues (2023) define it as generalized redness and scaling over more than 90 percent of the body surface area, while Singh and colleagues (2016) describe inflammatory redness over at least 75 percent.^[34][35] The word comes from erythroderma, the medical term for redness of almost all the skin, which is also called exfoliative dermatitis.

It is the rarest form of psoriasis. Singh and colleagues estimate that it affects about 1 to 2.25 percent of people with psoriasis.^[35] Most people who develop it already have plaque psoriasis, often unstable or poorly controlled.

What are the symptoms of erythrodermic psoriasis?

The skin over most of the body turns bright red or dusky, depending on skin tone, and sheds in fine flakes or large sheets rather than forming separate plaques. Many people feel intense itch, burning, or skin pain, along with chills, fever, fatigue, and swelling of the ankles or legs. Nails may thicken or shed, and hair can thin during a flare.

Why is erythrodermic psoriasis an emergency?

Skin that is inflamed almost everywhere stops working as a barrier. The body loses heat, fluid, and protein through the skin, which can lead to dangerously low body temperature, dehydration, low blood protein, and serious infections, and the extra blood flow to the skin can strain the heart in older adults. The medical board of the National Psoriasis Foundation (Rosenbach and colleagues, 2010) recommends assessing each patient for these complications first, and many people are admitted to hospital for fluids, temperature control, and wound care.^[36]

What triggers erythrodermic psoriasis?

The most commonly reported triggers are abrupt withdrawal of oral or injected corticosteroids, severe sunburn, infections, reactions to new medications, heavy alcohol use, emotional stress, and a sudden flare of existing plaque psoriasis. Stopping a systemic psoriasis medication without a plan can also tip unstable disease into erythroderma.^[5][35]

How is erythrodermic psoriasis treated?

Treatment starts with supportive care: rehydration, warm surroundings, bland emollients, wet wraps, mild topical corticosteroids, and treatment of any infection. In 2010 the National Psoriasis Foundation medical board advised cyclosporine or infliximab as first-line systemic therapy for unstable cases, with acitretin and methotrexate reserved for more stable cases.^[36] Later reviews, including Singh and colleagues (2016) and Potestio and colleagues (2023), describe growing case and trial data for ustekinumab, IL-17 inhibitors such as ixekizumab and secukinumab, and IL-23 inhibitors such as guselkumab and risankizumab.^[34][35]

Evidence for erythrodermic psoriasis is thinner than for plaque psoriasis because the condition is rare and most large biologic trials excluded it. Treatment choices therefore rest on case series, small studies, and expert consensus rather than head-to-head trials.

Is all body-wide redness erythrodermic psoriasis?

Erythroderma has several causes besides psoriasis. Dermatologists also consider severe atopic dermatitis, drug reactions, pityriasis rubra pilaris, and cutaneous T-cell lymphoma (including Sézary syndrome). A skin biopsy and a careful medication history help separate these, which matters because each one is treated differently.

What Causes Psoriasis?

Psoriasis arises from a combination of genetic susceptibility and environmental triggers. If one parent has psoriasis, a child has about a 10% chance of developing it. If both parents have it, that risk rises to roughly 50%.^[3]

The Immune System Gone Awry

At the molecular level, psoriasis is driven by an overactive immune response. Dendritic cells in the skin become activated and release IL-23, which stimulates T cells to produce IL-17 and IL-22. These cytokines tell skin cells (keratinocytes) to proliferate rapidly and recruit more immune cells, creating a self-perpetuating cycle of inflammation.^[2]

Genetic Factors

Over 80 genetic loci have been linked to psoriasis susceptibility. The strongest association is with HLA-Cw6, a gene in the major histocompatibility complex that plays a role in immune recognition. But genetics alone do not determine who gets psoriasis. Many people carry these gene variants without ever developing the disease. Something has to flip the switch.^[7]

The genome-wide study by Tsoi and colleagues in Nature Genetics (2012) added 15 new susceptibility loci and pointed to genes involved in innate immunity, the body’s first-line defense system.^[7] That finding helps explain why infections and skin injury can set off psoriasis in people who carry the risk genes.

Common Triggers

For people with a genetic predisposition, certain triggers can initiate or worsen psoriasis.

• Stress: This is one of the most commonly reported triggers. Psychological stress can activate immune pathways and worsen skin inflammation through neuroendocrine mechanisms. Many patients can trace their first outbreak to a major stressful life event.^[8]
• Infections: Streptococcal throat infections are the classic trigger for guttate psoriasis, but other infections (including HIV) can also trigger or worsen the disease.
• Skin injury (Koebner phenomenon): Psoriasis can develop at sites of skin trauma, including cuts, scrapes, sunburn, tattoos, and even friction from tight clothing. This phenomenon occurs in 25-50% of psoriasis patients.^[9]
• Medications: Lithium, beta-blockers, antimalarials, and rapid withdrawal of systemic corticosteroids are well-known psoriasis triggers. NSAIDs and ACE inhibitors may also worsen it in some individuals.
• Alcohol: Heavy alcohol consumption is associated with more severe psoriasis and reduced treatment response. Alcohol may worsen psoriasis through its effects on the immune system and liver metabolism of medications.^[10]
• Smoking: Current smokers have nearly double the risk of developing psoriasis compared to people who have never smoked. Smoking is particularly associated with pustular psoriasis of the palms and soles.^[10]
• Cold, dry weather: Many people with psoriasis notice their skin worsens in winter, when humidity drops and there is less natural UV exposure.

Keeping a simple flare diary, with dates, stressors, illnesses, new medications, and weather, often shows which triggers matter most for one person. Bring that record to appointments, because it helps a dermatologist decide whether a flare calls for a treatment change or for trigger control.

How Is Psoriasis Diagnosed?

Psoriasis is usually diagnosed by a dermatologist from the appearance of the skin, scalp, and nails, together with a personal and family history. No blood test confirms psoriasis. The exam looks for well-defined plaques, silvery scale, pinpoint bleeding when scale is lifted (the Auspitz sign), nail pitting, and involvement of the scalp, ears, navel, and buttock fold.

What tests confirm psoriasis?

When the picture is unclear, a small skin biopsy can confirm psoriasis under the microscope and rule out look-alikes such as eczema, seborrheic dermatitis, lichen planus, and cutaneous lymphoma. A skin scraping tested for fungus helps separate inverse psoriasis from a yeast or tinea infection in skin folds. For suspected guttate psoriasis, a throat swab or blood test can check for a recent streptococcal infection.^[4]

How do doctors measure psoriasis severity?

Dermatologists grade severity with a few standard tools. Body surface area (BSA) estimates how much skin is involved; the Psoriasis Area and Severity Index (PASI) combines redness, thickness, scaling, and extent into one score; and the Physician Global Assessment (PGA) rates the overall picture.^[10] Clinical trials report results as PASI 75, PASI 90, or PASI 100, meaning a 75, 90, or 100 percent improvement from baseline. Quality-of-life scores such as the Dermatology Life Quality Index (DLQI) capture what the numbers miss, and plaques on the face, palms, soles, genitals, or nails can count as severe even when the BSA is small.

What tests are needed before systemic treatment?

Before starting methotrexate, cyclosporine, or a biologic, doctors usually order blood counts, liver and kidney tests, and screening for hepatitis B and C. The joint AAD-NPF biologic guidelines (Menter and colleagues, 2019) recommend tuberculosis screening before biologic therapy begins.^[37] Many dermatologists also ask screening questions for psoriatic arthritis, such as the Psoriasis Epidemiology Screening Tool (PEST), at every visit.

Conventional Treatments

Psoriasis treatment is typically stepped based on severity. Mild disease (affecting less than 3% of the body surface) can often be managed topically. Moderate-to-severe disease usually requires phototherapy, systemic medications, or biologics.

The American Academy of Dermatology and the National Psoriasis Foundation publish joint guidelines for each step, including the 2019 guideline on biologics led by Menter and colleagues.^[11][37] The Regenerated.com guide to psoriasis treatment summarizes the same options by category.

Topical Treatments

Corticosteroids remain the most commonly prescribed topical treatment. For psoriasis, medium-to-high potency formulations are often needed given the thickness of the plaques. They reduce inflammation, itch, and scaling effectively but should be used in cycles to avoid side effects like skin thinning.^[11]

Vitamin D analogues (calcipotriol/calcipotriene, calcitriol) slow skin cell growth and are often combined with corticosteroids for enhanced effect. The combination of calcipotriol with betamethasone dipropionate is one of the most effective topical regimens available.

Tar preparations (coal tar) are among the oldest treatments for psoriasis and still work well for some patients, particularly for scalp psoriasis. They reduce scaling, itch, and inflammation, though the smell and staining can be drawbacks.

Topical retinoids (tazarotene) normalize skin cell growth but can cause irritation. They are often combined with a corticosteroid to improve tolerability.

Calcineurin inhibitors (tacrolimus, pimecrolimus), while primarily approved for eczema, are sometimes used off-label for psoriasis in sensitive areas like the face and skin folds.

Newer nonsteroidal topicals include roflumilast cream, a topical PDE4 inhibitor, and tapinarof cream, an aryl hydrocarbon receptor agonist. Both are prescription options for plaque psoriasis that avoid the skin thinning linked to long-term steroid use.

Phototherapy

Controlled exposure to ultraviolet light is one of the most effective treatments for moderate-to-severe psoriasis. Narrowband UVB (NB-UVB) is the most widely used form, typically administered two to three times per week in a dermatologist’s office or with a home unit. It slows skin cell turnover and reduces inflammation. About 70% of patients achieve significant clearance with NB-UVB.^[12]

PUVA (psoralen plus UVA) involves taking a light-sensitizing medication before UVA exposure. It is very effective but carries a higher long-term risk of skin cancer, so it is used more selectively.

Excimer laser delivers targeted UVB to individual plaques, which is useful for stubborn spots that have not responded to other treatments.

Systemic Medications

When topicals and phototherapy are not enough, oral or injectable systemic medications may be needed.

Methotrexate has been used for psoriasis since the 1950s and remains a reliable option. It suppresses the overactive immune response and is taken once weekly. It requires monitoring of blood counts and liver function, and it cannot be used during pregnancy.^[13]

Cyclosporine works quickly and effectively but is generally limited to short-term use (one to two years) due to risks of kidney damage and high blood pressure.

Acitretin is an oral retinoid that is particularly useful for pustular psoriasis. It works best in combination with phototherapy. Like all retinoids, it is teratogenic and requires strict pregnancy prevention.

Apremilast (Otezla) is a PDE4 inhibitor taken orally that is well-tolerated compared to older systemics. It is less potent than biologics but does not require lab monitoring and may suit patients with mild-to-moderate disease who want an oral option.^[14]

Deucravacitinib is a newer once-daily oral drug that blocks TYK2, an enzyme that carries IL-23 and IL-12 signals inside immune cells. It is approved for adults with moderate-to-severe plaque psoriasis and gives people who prefer pills another option between apremilast and injectable biologics.

Biologics

Biologic therapies have transformed the treatment of moderate-to-severe psoriasis. These are protein-based drugs, given by injection or infusion, that target specific parts of the immune system.

TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab) were the first wave of biologics for psoriasis. They block TNF-alpha, a major inflammatory cytokine. They remain effective options, though newer agents tend to outperform them.^[15]

IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) target IL-17A, a cytokine central to psoriatic inflammation. They produce high rates of skin clearance, with many patients achieving PASI 90 (90% improvement) or even PASI 100 (complete clearance).^[16]

IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) target the p19 subunit of IL-23, which is upstream in the inflammatory cascade. These agents require fewer injections (often just every 8 to 12 weeks after loading doses) and produce durable, sustained clearance. Risankizumab and guselkumab have shown particularly impressive long-term results.^[17]

IL-12/23 inhibitor (ustekinumab) targets both IL-12 and IL-23. It was one of the first biologics to show that targeting specific interleukins could produce dramatic skin clearance. It requires only four injections per year.

The choice between biologics depends on individual factors including disease severity, comorbidities, convenience, and insurance coverage. Your dermatologist can help navigate these options.

Biosimilars, which are lower-cost versions of off-patent biologics such as adalimumab and ustekinumab, are now available in the United States and work the same way as the original drugs. The psoriasis biologics comparison goes deeper into each class.

How do the main psoriasis treatments compare?

Psoriasis treatments differ in how they are given, how quickly they work, and what monitoring they need. The table below restates the facts given in the sections above.

Integrative and Regenerative Approaches

While biologics and other conventional therapies form the backbone of psoriasis treatment, integrative strategies can support overall health and may reduce disease activity.

Anti-Inflammatory Diet

There is growing evidence that diet affects psoriasis severity. A Mediterranean-style diet rich in fruits, vegetables, fish, olive oil, and whole grains has been associated with less severe psoriasis in observational studies. Conversely, diets high in processed foods, sugar, and saturated fat are linked to worse outcomes.^[18]

Weight management deserves special mention. Obesity is both a risk factor for developing psoriasis and a driver of more severe disease. Fat tissue produces inflammatory cytokines (including TNF-alpha) that feed the psoriatic inflammatory cycle. Studies have shown that weight loss, whether through diet, exercise, or bariatric surgery, can significantly improve psoriasis severity and treatment response.^[19]

Some patients report improvement with gluten-free diets, particularly those with elevated antibodies to gliadin. If you suspect gluten sensitivity, a trial elimination with careful monitoring is reasonable, but blanket gluten avoidance is not necessary for everyone with psoriasis.

Vitamin D

Vitamin D plays a well-established role in psoriasis. It regulates keratinocyte growth and differentiation, which is why vitamin D analogues are a mainstay of topical treatment. Low serum vitamin D levels are common in psoriasis patients and are associated with greater disease severity. Supplementation to reach optimal levels (40 to 60 ng/mL) is reasonable and safe for most people, though oral vitamin D alone is not a substitute for direct psoriasis treatment.^[20]

Omega-3 Fatty Acids

Fish oil, rich in EPA and DHA, has anti-inflammatory effects that may benefit psoriasis. A meta-analysis of clinical trials found modest improvements in psoriasis severity with omega-3 supplementation, particularly in patients who were also receiving standard treatment. Doses used in studies typically range from 2 to 4 grams of combined EPA and DHA daily.^[21]

Turmeric and Curcumin

Curcumin, the active compound in turmeric, has documented anti-inflammatory and immunomodulatory properties. Some small clinical studies have shown improvement in psoriasis symptoms with oral curcumin supplementation or topical curcumin preparations. Bioavailability is a challenge with oral curcumin; formulations with piperine (black pepper extract) or phospholipid complexes improve absorption significantly.^[22]

The oral curcumin trial by Kurd and colleagues (2008) was small and had no placebo group, so it shows that curcumin is worth studying rather than that it works.^[22] Curcumin can interact with blood thinners, so mention it to the clinician who manages your medications.

Stress Management

Given the strong link between stress and psoriasis flares, stress reduction is not just a nice idea; it is a therapeutic strategy. Mindfulness-based stress reduction (MBSR), meditation, and cognitive behavioral therapy have all shown benefit in psoriasis patients. One well-known study by Jon Kabat-Zinn found that patients who listened to guided meditation tapes during phototherapy cleared their psoriasis significantly faster than those who received phototherapy alone.^[23]

Red Light Therapy (Photobiomodulation)

Distinct from the UV phototherapy used in clinical settings, red and near-infrared light therapy works through different mechanisms: stimulating mitochondrial function, reducing oxidative stress, and modulating inflammation. While it is not a primary treatment for psoriasis, some studies suggest it may be a helpful adjunct, particularly for localized plaques and for reducing inflammation associated with psoriatic arthritis. More research is needed, but the favorable safety profile makes it worth considering.^[24]

Dead Sea Therapy (Climatotherapy)

Bathing in the mineral-rich waters of the Dead Sea combined with controlled sun exposure has been used for psoriasis treatment for decades. The Dead Sea sits at the lowest point on Earth, and the thick atmosphere filters out some of the sun’s burning rays while allowing therapeutic UVA and UVB through. Studies have shown significant psoriasis improvement with Dead Sea climatotherapy programs, typically lasting three to four weeks. While traveling to the Dead Sea is not practical for everyone, Dead Sea salt baths at home may offer some benefit.^[25]

Clinic-Based Regenerative Therapies: What the Evidence Shows

Some integrative and regenerative clinics offer ozone therapy, IV vitamin infusions, or stem cell therapy for psoriasis. None of these is FDA-approved for psoriasis, they are usually paid out of pocket, and published human data are limited to small studies or early-phase trials. Mesenchymal stem cell treatment for psoriasis remains investigational, and current studies are listed on ClinicalTrials.gov.

If you consider one of these options, treat it as an add-on to dermatology care rather than a replacement, ask what outcome the clinic measures, and keep your dermatologist informed. A well-run integrative practice will coordinate with your prescribing doctor rather than ask you to stop a working medication.

Psoriasis vs. Eczema: How to Tell Them Apart

These two conditions are sometimes confused, but they are fundamentally different diseases with different underlying mechanisms.

• Appearance: Psoriasis plaques are typically well-defined, thick, and covered with silvery scales. Eczema patches tend to be less defined, thinner, and may weep or crust.
• Location: Psoriasis favors the outer surfaces of joints (elbows, knees), the lower back, and the scalp. Eczema tends to appear in the creases (inner elbows, behind the knees).
• Itch quality: Both conditions itch, but eczema itch is usually more intense and described as burning or stinging. Psoriasis itch is often described as more of a surface-level irritation.
• Age of onset: Eczema commonly starts in infancy and often improves with age. Psoriasis more often begins in adolescence or adulthood.
• Immune pathway: Eczema is Th2-driven; psoriasis is Th17/Th1-driven. This is why they respond to different medications.

It is possible, though uncommon, to have both conditions simultaneously.

The difference matters most when the whole body is red. Both severe eczema (atopic dermatitis) and psoriasis can progress to erythroderma, and a biopsy is often the only way to tell which disease is behind it, because a drug that targets the Th2 pathway helps eczema while IL-17 and IL-23 drugs help psoriasis. The eczema condition page describes atopic dermatitis on its own terms.

Psoriatic Arthritis: The Joint Connection

Up to 30% of people with psoriasis develop psoriatic arthritis (PsA), an inflammatory arthritis that can cause joint pain, stiffness, swelling, and, if untreated, permanent joint damage. PsA can affect any joint but commonly involves the fingers, toes, lower back, and the points where tendons and ligaments attach to bone (enthesitis).^[26]

Early detection is critical. Joint damage from PsA can begin before you notice symptoms, so if you have psoriasis and experience any joint pain, stiffness (especially morning stiffness lasting more than 30 minutes), swollen fingers or toes (“sausage digits”), or lower back pain, bring it up with your doctor promptly.

Many of the biologic treatments used for skin psoriasis are also effective for PsA, which is an advantage for patients dealing with both.

Psoriatic arthritis is diagnosed and managed by a rheumatologist, often alongside the dermatologist, and nail psoriasis is one of the strongest warning signs for it. The psoriatic arthritis symptoms guide lists the early joint signs to report, and the arthritis condition overview compares PsA with other inflammatory joint diseases.

Comorbidities: Psoriasis as a Systemic Disease

Psoriasis is increasingly recognized as more than a skin disease. The chronic systemic inflammation it generates affects multiple organ systems.

Cardiovascular Disease

People with moderate-to-severe psoriasis have a higher risk of heart attack, stroke, and cardiovascular mortality. The chronic inflammation driving psoriasis also promotes atherosclerosis (the buildup of plaques in arteries). This risk exists even after accounting for traditional risk factors like smoking, obesity, and diabetes. Effective treatment of psoriasis may reduce this cardiovascular risk.^[27]

The cohort study by Gelfand and colleagues in JAMA (2006) found that the excess risk of heart attack was highest in younger adults with severe psoriasis.^[27] For that reason, people with psoriasis benefit from regular blood pressure, cholesterol, and blood sugar checks with their primary care physician.

Metabolic Syndrome

Psoriasis is associated with higher rates of obesity, type 2 diabetes, high blood pressure, and abnormal cholesterol levels. The relationship is bidirectional: obesity worsens psoriasis, and psoriasis-related inflammation contributes to metabolic dysfunction.

Mental Health

Depression and anxiety are significantly more common in people with psoriasis than in the general population. The visible nature of the disease, the unpredictability of flares, and the chronic itch all take a psychological toll. Studies have found that the quality-of-life impact of psoriasis is comparable to that of cancer and heart disease.^[28]

This is not something to push through or ignore. If psoriasis is affecting your mood, self-image, or relationships, talk to your healthcare team. Psychological support should be considered part of standard psoriasis care.

The Cost of Treatment

The financial burden of psoriasis is significant. Biologic therapies, while highly effective, carry list prices that often exceed $50,000 to $70,000 per year in the United States. With insurance, copays can still be substantial, though most manufacturers offer patient assistance programs that can significantly reduce out-of-pocket costs.

Even without biologics, the costs add up: topical medications, doctor visits, phototherapy sessions, and lost productivity. Studies estimate the total annual cost of psoriasis in the U.S. at over $100 billion when both direct medical costs and indirect costs (lost work, reduced productivity) are included.^[29]

If cost is a barrier, talk to your dermatologist about it directly. There are often options: patient assistance programs, biosimilars (lower-cost versions of biologic drugs), step therapy approaches, or combinations of less expensive treatments that can still provide good results.

Integrative services such as nutrition counseling, supplements, red light sessions, and regenerative procedures are usually cash pay and rarely covered by insurance. Ask any clinic for a written estimate of the full course before you start, since prices vary widely between practices.

Choosing Between Treatment Options

With so many options available, choosing the right treatment can feel overwhelming. Here are some guiding principles.

1. Match treatment intensity to disease severity. Mild, localized psoriasis may only need topicals. Widespread or resistant disease usually requires systemic therapy.
2. Consider the whole picture. If you also have psoriatic arthritis, a biologic that treats both skin and joints makes more sense than a topical-only approach.
3. Think about lifestyle. How do you feel about self-injections? Can you commit to phototherapy three times a week? Do you need something that works fast for an upcoming event? These practical factors matter.
4. Factor in comorbidities. Some treatments, like methotrexate, require liver monitoring and are not ideal if you consume alcohol regularly. Others, like cyclosporine, are problematic if you have high blood pressure.
5. Set realistic goals. Modern biologics can achieve near-complete clearance for many patients, but this may take several months. Discuss treatment targets with your dermatologist, and give each therapy adequate time before deciding it has failed.
6. Do not neglect the basics. Even on a biologic, consistent moisturizing, trigger avoidance, stress management, and a healthy diet remain important foundations.

One situation overrides this step-by-step approach. Redness spreading over most of the body, widespread pustules, fever, chills, or feeling faint during a flare point to erythrodermic or generalized pustular psoriasis, and those need same-day emergency care rather than a routine appointment.

Who Treats Psoriasis and How to Find Care

A board-certified dermatologist leads psoriasis care, prescribes topicals, phototherapy, and systemic drugs, and decides when a biologic is appropriate. A rheumatologist joins when joint symptoms suggest psoriatic arthritis, and a primary care physician tracks blood pressure, cholesterol, blood sugar, and weight. Psychologists, registered dietitians, and integrative or functional medicine physicians can support stress, diet, and lifestyle goals alongside that core team.

The Regenerated.com directory of clinics offering psoriasis treatment lists practices across the United States, from dermatology-led clinics to integrative practices. Listing order on Regenerated.com is not paid ranking, Featured slots are labeled and capped, Verified means the clinic completed credential checks rather than paying for placement, and the directory is free for patients. Inclusion in the directory is not an endorsement, and the guide to Featured, Verified, and organic listings explains each label.

When you contact a clinic, ask who will examine your skin, whether a dermatologist is involved in diagnosis and prescribing, which psoriasis types they treat, and how they coordinate with your other doctors. Those answers say more about fit than any listing badge.

The Bottom Line

Psoriasis is a chronic condition, but “chronic” does not have to mean “controlling your life.” The treatment options available today are better than they have ever been, and a growing understanding of the disease is opening doors to even more targeted therapies.

Whether you manage your psoriasis with topical creams, phototherapy, biologics, lifestyle changes, or some combination of all of these, the goal is the same: clear skin, healthy joints, and a life not defined by your diagnosis. Work with a dermatologist who listens, stay informed about new developments, and do not underestimate the value of the integrative strategies that support your whole-body health.

Know the one form that cannot wait. Erythrodermic psoriasis, defined as redness and scaling over more than 90 percent of the body, is rare but dangerous, and it needs emergency assessment rather than a change in skin care. For every other form, a clear diagnosis, a severity score, and a stepped treatment plan give the best chance of lasting control. Clinicians who manage psoriasis can be found through the national psoriasis clinic directory.

Frequently Asked Questions

How well do biologics work for psoriasis?

Biologics clear most or all psoriasis plaques for many people with moderate-to-severe disease. IL-17 inhibitors such as secukinumab and ixekizumab let many patients reach PASI 90, a 90 percent improvement, or PASI 100, complete clearance, according to the phase 3 secukinumab trials by Langley and colleagues (2014). IL-23 inhibitors such as guselkumab and risankizumab need injections only every 8 to 12 weeks, and ustekinumab needs four a year. Full results can take several months.

How much do psoriasis biologics cost?

Psoriasis biologics carry US list prices that often exceed $50,000 to $70,000 per year, although insurance, manufacturer assistance programs, and biosimilars can lower what a patient pays. Counting medical care, lost work, and reduced productivity, psoriasis costs the United States over $100 billion a year, according to Brezinski and colleagues in JAMA Dermatology (2015). Cost-sensitive patients can ask about biosimilars, step therapy, or combinations of less expensive treatments.

What are the side effects and safety concerns with psoriasis medications?

Each psoriasis medication class has its own cautions. Strong topical corticosteroids can thin the skin with long continuous use. Methotrexate needs blood count and liver monitoring and cannot be used in pregnancy. Cyclosporine is limited to about one to two years because of kidney and blood pressure risks. Acitretin and other oral retinoids cause birth defects and require strict pregnancy prevention. PUVA raises long-term skin cancer risk, and biologics require tuberculosis screening before the first dose.

Do diet and supplements help with psoriasis?

Diet and supplements can modestly support psoriasis care but do not replace medical treatment. A Mediterranean-style diet and weight loss are linked to milder disease. Vitamin D supplementation to reach 40 to 60 ng/mL is reasonable when levels are low, and a meta-analysis by Clark and colleagues (2019) found modest benefit from 2 to 4 grams of omega-3 EPA and DHA daily. Curcumin has shown promise in small studies, but its absorption is poor.

How quickly does phototherapy clear psoriasis?

Narrowband UVB phototherapy, given two to three times a week, brings significant clearance for about 70 percent of patients, usually over a course of several weeks, according to a systematic review by Archier and colleagues (2012). In a study by Kabat-Zinn and colleagues (1998), patients who listened to guided meditation during light treatment cleared faster than those who did not. Dead Sea climatotherapy programs, a natural form of light therapy, typically run three to four weeks.

Which psoriasis treatment is right for me?

The right psoriasis treatment depends mainly on severity, location, and whether your joints are involved. Mild disease covering less than 3 percent of the body is usually treated with topicals, while moderate-to-severe disease may need phototherapy, oral systemic drugs, or biologics. Because up to 30 percent of people with psoriasis develop psoriatic arthritis, joint symptoms often favor a biologic that treats skin and joints together. Body-wide redness or pustules need emergency care first.

Sources

1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6 ↩
2. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004 ↩
3. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi:10.1038/jid.2012.339 ↩
4. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39-42. doi:10.1001/archderm.1992.01680110049004 ↩
5. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144. doi:10.2147/PTT.S98954 ↩
6. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27. doi:10.1016/j.jaad.2005.07.073 ↩
7. Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341-1348. doi:10.1038/ng.2467 ↩
8. Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50(7):783-792. doi:10.1111/j.1365-4632.2010.04844.x ↩
9. Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol. 2011;29(2):231-236. doi:10.1016/j.clindermatol.2010.09.014 ↩
10. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Clin Exp Dermatol. 2010;35(5):464-468. doi:10.1111/j.1365-2230.2010.03826.x ↩
11. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60(4):643-659. doi:10.1016/j.jaad.2008.12.032 ↩
12. Archier E, Devaux S, Castela E, et al. Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):11-21. doi:10.1111/j.1468-3083.2012.04519.x ↩
13. Bangert C, Binder M. Methotrexate in dermatology. Dermatol Ther. 2022;35(1):e15169. doi:10.1111/dth.15169 ↩
14. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2015;73(1):37-49. doi:10.1016/j.jaad.2015.03.049 ↩
15. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. doi:10.1016/j.jaad.2007.09.010 ↩
16. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi:10.1056/NEJMoa1314258 ↩
17. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2). Lancet. 2018;392(10148):650-661. doi:10.1016/S0140-6736(18)31713-6 ↩
18. Barrea L, Nappi F, Di Somma C, et al. Environmental risk factors in psoriasis: the point of view of the nutritionist. Int J Environ Res Public Health. 2016;13(5):743. doi:10.3390/ijerph13070743 ↩
19. Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633-639. doi:10.1159/000455840 ↩
20. Orgaz-Molina J, Buendia-Eisman A, Arrabal-Polo MA, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol. 2012;67(5):931-938. doi:10.1016/j.jaad.2012.01.040 ↩
21. Clark CCT, Taghizadeh M, Nahavandi M, Jafarnejad S. Efficacy of omega-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials. Clin Rheumatol. 2019;38(4):977-988. doi:10.1007/s10067-019-04456-x ↩
22. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad Dermatol. 2008;58(4):625-631. doi:10.1016/j.jaad.2007.12.035 ↩
23. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60(5):625-632. doi:10.1097/00006842-199809000-00020 ↩
24. Ablon G. Phototherapy with light emitting diodes: treating a broad range of medical and aesthetic conditions in dermatology. J Clin Aesthet Dermatol. 2018;11(2):21-27. PMID: 29552273 ↩
25. Harari M, Shani J, Hristakieva E, et al. Climatotherapy of atopic dermatitis at the Dead Sea: demographic evaluation and cost-effectiveness. Int J Dermatol. 2000;39(1):59-69. doi:10.1046/j.1365-4362.2000.00840.x ↩
26. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970. doi:10.1056/NEJMra1505557 ↩
27. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741. doi:10.1001/jama.296.14.1735 ↩
28. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401-407. doi:10.1016/S0190-9622(99)70112-X ↩
29. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States. JAMA Dermatol. 2015;151(6):651-658. doi:10.1001/jamadermatol.2014.3593 ↩
30. Eczema: A Complete Guide to Understanding and Managing Eczema
31. Red Light Therapy: What the Evidence Actually Shows
32. The Anti-Inflammatory Diet: A Practical Guide
33. Vitamin D: Why Most People Are Deficient and What to Do About It
34. Potestio L, Camela E, Cacciapuoti S, et al. Biologics for the management of erythrodermic psoriasis: an updated review. Clin Cosmet Investig Dermatol. 2023;16:2045-2059. doi:10.2147/CCID.S407813 ↩
35. Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93-104. doi:10.2147/PTT.S101232 ↩
36. Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655-662. doi:10.1016/j.jaad.2009.05.048 ↩
37. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057 ↩
38. Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563 ↩